BCRX
BioCryst Pharmaceuticals Inc
8.80$
+0.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.0% | -27.9% | +98.4% | -17.6% | +19.4% | +91.0% | +75.7% | -6.5% | -6.0% | -5.1% | +4.8% | |
| – | -26.1% | +1.5% | +87.2% | -8.8% | +43.7% | +97.0% | +74.8% | -8.8% | -4.0% | -14.9% | -4.2% | |
| – | -47.0% | -23.5% | +127.5% | -46.8% | +327.1% | +138.3% | +85.4% | -39.6% | -63.7% | -5.2% | -14.5% | |
| – | -12.9% | -35.9% | +144.9% | -18.5% | +7.4% | +120.5% | +69.0% | -16.4% | -8.3% | -17.5% | -14.4% | |
| – | -34.2% | +40.4% | -30.2% | -29.8% | +415.9% | -61.0% | +240.2% | +72.0% | +12.6% | +38.8% | +35.1% | |
| – | +136.0% | -69.0% | -7,659.8% | – | -5.9% | +353.8% | +124.3% | +74.4% | +4.2% | -71.8% | -33.3% | |
| – | +2,387.4% | +92.7% | -3.8% | -4.3% | -19.6% | -3.2% | +113.5% | +1.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +25.5% | +14.9% | +7.1% | +3.3% | +40.4% | +158.3% | +96.4% | +21.5% | +15.1% | -0.6% | -34.5% | |
| – | +11.7% | -15.7% | +37.7% | -7.2% | +32.9% | +14.4% | -1.8% | +1.7% | +42.1% | +6.9% | +22.2% | |
| – | -7.3% | +1.6% | +24.7% | -4.2% | +18.4% | -22.0% | -94.2% | +30.2% | +11.8% | +1,238.7% | -95.4% | |
| – | +226.7% | -54.1% | +48.4% | +22.6% | +80.0% | +33.8% | +48.6% | -48.4% | +45.5% | -44.3% | +35.9% | |
| – | – | +859.0% | -26.5% | +51.5% | +62.7% | +190.0% | +389.0% | +25.2% | +10.6% | -1.9% | -46.3% | |
| – | – | – | – | – | – | -150.4% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +9.2% | +1.1% | +14.6% | +22.2% | +12.0% | +44.7% | +7.1% | +3.8% | +3.4% | +7.5% | +5.7% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.